
    
      This study is a prospective, randomized, placebo-controlled, blinded, dose escalation study
      of 3 to 4 cohorts with defined number of patients per cohort receiving active drug or placebo
      for a period of 4 months followed by safety monitoring for an additional 4 months after the
      last dose
    
  